

Special Issue

Inflammatory and Immunological Markers in Liver Cancers

Message from the Guest Editor

Liver cancer (hepatocellular and colangiocharcinoma) is the second most common cause of cancer deaths worldwide. Inflammation has been recognized as sign of cancer and is known to play an important role in the deterioration and progression of most tumors, even those that have no visible signs of inflammation and infection. Liver inflammation is regulated by chemokines, which regulate the migration and activities of hepatocytes, Kupffer cells, hepatic stellate cells, endothelial cells, and circulating immune cells.

Emerging experimental data indicate that the presence of a preexisting intratumoral T-cell infiltration, interferon (IFN) signaling, checkpoint molecules (PD-1, PD-L1 expression) or high tumor mutational burden could favor a clinical response. In recent years, immune checkpoint inhibitors, which unleash the body's own immune response to attack tumors by targeting regulatory pathways in T cells, have shown remarkable efficacy in liver cancers. If the relationship between inflammatory factors, immunological setting and liver cancers can be found, it may provide new directions for treatment of liver cancer. This special issue wants to focus on these aspects.

Guest Editor

Dr. Andrea Dalbeni

Section of General Medicine C and Liver Unit, University of Verona, Verona, Italy

Deadline for manuscript submissions

closed (31 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/153247

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)